SpliceBio will use its €50 million in financing to advance development of a gene therapy for Stargardt disease, a rare eye disorder. The biotech’s technology enables the delivery of genes that are too large for the capacity of the adeno-associated viruses widely used in the delivery of genetic medicines.
Neuroelectrics is planning a pivotal test of its wearable medical device, which delivers brain electrical stimulation to treat epilepsy. The startup's Series A round of funding was led by Morningside Ventures.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Researchers in Spain, one of Europe's worst-hit countries, randomly selected more than 61,000 people, but found that even in places with high infection rates like Madrid, relatively few people tested positive for antibodies against SARS-CoV-2.
In an interview with MedCity News, the founder and CSO of Spanish biotech startup Libera Bio talked about her company's ambitions to apply its precision medicine technologies for the treatment of different types of cancer.
The biotech company presented data for AMG 510 at the European Society for Medical Oncology during the weekend. Although the drug showed activity, the data got mixed reactions from investment bank analysts.
The company announced the presentation of data at the ESMO meeting in Barcelona for Tibsovo, in patients with IDH1-mutant bile duct cancer. The drug is approved for treating IDH1-mutation positive acute myeloid leukemia.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Data for AstraZeneca's Imfinzi showed an improvement in overall survival and duration of response in patients with first-line extensive-stage small-cell lung cancer. Roche's Tecentriq already has approval in that indication.
Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose.
Analysts nevertheless wrote that with each data update, Lilly's RET inhibitor LOXO-292 (selpercatinib) appears less differentiated on efficacy as well as tolerability from Blueprint Medicines' BLU-667 (pralsetinib).
Several patients in the trial of CYAD-101 combined with chemotherapy responded to treatment, but both a company executive and a gastrointestinal cancer expert cautioned the data were too preliminary to draw conclusions.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The deal increases Centene's ownership of the Spanish provider Ribera Salud from 50 percent to 90 percent.
An enormous ransomware attack has impacted organizations across the globe, including the National Health Service. U.K. hospitals resorted to diverting patients and using pen and paper for documentation.
Nearly a year after its acquisition of Withings, Nokia highlighted product development news for digital health devices.
See the best and worst from Mobile World Congress, plus new Microsoft security features and thoughts on the Apple encryption battle.
This is the physician social network's first foray into non-English-speaking countries.